Finally, although studies of histological outcomes related to MASLD with the use of SGLT2 inhibitors are scarce, there is evidence of reduction in liver enzymes, liver fat, and liver stiffness assessed with elastography as a result of the use of those drugs in a population with T2DM.316-318 Thus, some guidelines for the management of MASLD recommend that treatment with SGLT2 inhibitors be considered for individuals with T2DM and MASH and/or fibrosis, without sex-related difference regarding outcomes.295,298,308. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.